<DOC>
	<DOCNO>NCT02182375</DOCNO>
	<brief_summary>Study investigate effect UGT1A1 inhibition single multiple oral dos BI 201335 single multiple oral dose pharmacokinetics raltegravir investigate safety tolerability .</brief_summary>
	<brief_title>Effect BI 201335 Mediated UGT1A1 ( Uridine-diphosphate-glucuronosyltransferases ) Inhibition Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Healthy male female Age range ≥ 21 ≤ 50 year Body mass index ( BMI ) ≥ 18.5 ≤ 29.9 kg/m2 Willing complete studyrelated activity include genotyping Volunteers give write informed consent prior admission study Any finding medical examination ( include blood pressure , pulse rate ECG ( Electrocardiogram ) ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder , clinically relevant electrolyte disturbance Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History photosensitivity recurrent rash History orthostatic hypotension , faint spell blackouts Chronic clinically relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24:00 hour ) within least one month less ten halflives respective drug enrolment study study ( exception hormonal contraceptive ) Use drug might influence result trial 7 day prior enrolment trial trial Participation another trial investigational drug ( within two month prior administration trial ) Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation ( &gt; 100 mL within four week prior administration trial ) Any laboratory value outside reference range indicative underlying disease poor health Excessive physical activity within last week trial trial Hypersensitivity treatment medication and/or relate drug class A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTcF , QTcB interval &gt; 450 m ) Vulnerable subject ( person keep detention ) The subject able understand comply protocol requirement , instruction protocolstated restriction For Female Subjects : Pregnancy Positive pregnancy test Lactation period No adequate contraception : female participate study must either ( 1 ) nonchildbearing potential ( e.g . surgically sterilize postmenopausal menstrual bleeding least 2 year prior study ) , ( 2 ) use one follow contraceptive method plus condom course study one month ( i.e . one complete menstrual cycle ) last administration study drug ( whichever longer ) : implant levonorgestrel injectable progestogen , oral contraceptive combine progestogen , intrauterine device ( IUD ) IUD publish data show low expected failure rate le 1 % per year ( IUDs meet criterion ) For Male Subjects : No adequate contraception : ( 1 ) surgically sterilize ( 2 ) use condom plus another form contraception ( e.g . spermicide , IUD , birth control pills take female partner , diaphragm spermicide ) . Male subject must father child administration first dose 3 month last dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>